Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients

• Status: ENROLLING_BY_INVITATION
• Trial end date: 2028-07-31

Summary

1. Conduct a large-sample, multicenter, superiority, double-blind, randomized controlled clinical trial to verify the efficacy of TJC in reducing the risk of cardiovascular and cerebrovascular events in patients with metabolic syndrome at high cardiovascular and cerebrovascular risk (HCR-MS).

2. Further construct an evaluation system for the long-term cardiovascular and cerebrovascular benefits of traditional Chinese medicine in regulating glucose and lipid metabolism through the evaluative study of the cardiovascular and cerebrovascular benefits of TJC.

• Phase: PHASE3

Details

• Lead Sponsor: Guangdong Provincial Hospital of Traditional Chinese Medicine
• Collaborators: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; Shanxi Provincial hospital of Chinese Medicine; TCM hospital of Sichuan Province; The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine; Xiyuan Hospital of CACMS; Yinchuan Brain-Heart Simultaneous Treatment Internet Hospital Co., Ltd
• Treatments: Color; Dosage Forms; Taste; Weights and Measures